Diabetes And Diagnostics Drive Abbott’s Growth In Q1
COVID-19 continues to hinder Abbott’s heart failure and neuromodulation business, but sales of COVID-19 tests drove unprecedented growth in the diagnostics business.
COVID-19 continues to hinder Abbott’s heart failure and neuromodulation business, but sales of COVID-19 tests drove unprecedented growth in the diagnostics business.